医学
累积发病率
氟达拉滨
外科
移植
再生障碍性贫血
入射(几何)
养生
内科学
全身照射
贫血
胃肠病学
环磷酰胺
化疗
骨髓
物理
光学
作者
HL Liu,Z-M Sun,L-Q Geng,X B Wang,K-y Ding,B-I Tang,Juan Tong,ZY Wang
摘要
We report a single-center experience in treating 18 consecutive patients with severe aplastic anemia (SAA) who received unrelated cord blood transplantation (CBT). The median age was 17 years (range 5–61 years). Sixteen cases received a reduced-intensity regimen composed of CY (total dose1200 mg/m2), rabbit antithymocyte globulin (ATG, total dose 30 mg/kg) and fludarabine (FLU, total dose 120 mg/m2). CYA and mycophenolate mofetil were used as GVHD prophylaxis. Two patients were not evaluable for engraftment because of early death on day +21 and +22. Only one of the sixteen cases achieved engraftment, but experienced secondary graft failure 3 months post transplantation. Fifteen patients experienced primary graft rejection, but all of them acquired autologous recovery. The 3-month and 6-month cumulative incidence of response was 56% and 81%, respectively. So far, 16 patients have survived for 330–1913 days (median, 750 days) after transplantation. The probability of OS at 2 years was 88.9%. Our data indicate that CBT for newly diagnosed SAA using no irradiation but FLU and ATG-based conditioning still seems to inevitably lead to the high risk of rejection, but may facilitate autologous recovery and improve survival with low risk of transplant-related mortality.
科研通智能强力驱动
Strongly Powered by AbleSci AI